Primary Category:
Treatment Protocols
Disease Category:
Lung - Small Cell Extensive Stage
Status:
Open
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
S1929, Step 1 Screening Registration is permanently closed to accrual, effective August 15, 2022, at 3:45am PT. Step 2 Randomization remains open until further notice.
NCT#04334941
